BPCR vs. ABDN, ATST, PHLL, 3IN, JGGI, BUR, RCP, BPT, EMG, and MNKS
Should you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include abrdn (ABDN), Alliance Trust (ATST), Petershill Partners (PHLL), 3i Infrastructure (3IN), JPMorgan Global Growth & Income (JGGI), Burford Capital (BUR), RIT Capital Partners (RCP), Bridgepoint Group (BPT), Man Group (EMG), and Monks (MNKS). These companies are all part of the "asset management" industry.
BioPharma Credit vs. Its Competitors
BioPharma Credit (LON:BPCR) and abrdn (LON:ABDN) are both financial services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.
BioPharma Credit has higher revenue and earnings than abrdn. BioPharma Credit is trading at a lower price-to-earnings ratio than abrdn, indicating that it is currently the more affordable of the two stocks.
abrdn has a consensus target price of GBX 184.33, suggesting a potential downside of 9.55%. Given abrdn's stronger consensus rating and higher possible upside, analysts plainly believe abrdn is more favorable than BioPharma Credit.
BioPharma Credit has a net margin of 80.20% compared to abrdn's net margin of 21.19%. BioPharma Credit's return on equity of 8.51% beat abrdn's return on equity.
41.5% of BioPharma Credit shares are owned by institutional investors. Comparatively, 38.2% of abrdn shares are owned by institutional investors. 6.2% of BioPharma Credit shares are owned by company insiders. Comparatively, 2.4% of abrdn shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, abrdn had 2 more articles in the media than BioPharma Credit. MarketBeat recorded 2 mentions for abrdn and 0 mentions for BioPharma Credit. BioPharma Credit's average media sentiment score of 0.00 equaled abrdn'saverage media sentiment score.
BioPharma Credit has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, abrdn has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.
BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 804.6%. abrdn pays an annual dividend of GBX 15 per share and has a dividend yield of 7.4%. BioPharma Credit pays out 7,957.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. abrdn pays out 85.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Summary
abrdn beats BioPharma Credit on 9 of the 17 factors compared between the two stocks.
Get BioPharma Credit News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
BioPharma Credit Competitors List
Related Companies and Tools
This page (LON:BPCR) was last updated on 7/27/2025 by MarketBeat.com Staff